	US 12,458,609 B2
	Dextroamphetamine and lisdexamfetamine to reverse dexmedetomidine sedation
Ken Solt, Lexington, MA (US); Oluwaseun Johnson-Akeju, Lexington, MA (US); and Emery N. Brown, Brookline, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Appl. No. 17/415,229
Filed by The General Hospital Corporation, Boston, MA (US)
PCT Filed Dec. 19, 2019, PCT No. PCT/US2019/067591 § 371(c)(1), (2) Date Jun. 17, 2021, PCT Pub. No. WO2020/132310, PCT Pub. Date Jun. 25, 2020.
Claims priority of provisional application 62/782,097, filed on Dec. 19, 2018.
Prior Publication US 2022/0062206 A1, Mar. 3, 2022
Int. Cl. A61K 31/165 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61P 25/26 (2006.01)

CPC A61K 31/165 (2013.01) [A61K 9/0019 (2013.01); A61K 31/137 (2013.01); A61P 25/26 (2018.01)]

19 Claims

1. A method for reversing dexmedetomidine sedation or facilitating emergence from dexmedetomidine sedation in a subject, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising dextroamphetamine, or a pharmaceutically acceptable salt thereof; lisdexamfetamine, or a pharmaceutically acceptable salt thereof, or a combination thereof.